Rigel Pharmaceuticals (FRA:RI2) Short Ratio


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
17 GF Score
Price €37.26
GF Value €24.49
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:RI2
17GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €37.26 is trading 52.1% above its estimated GF Value™ of €24.49. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:RI2:

  • Short Ratio:
  • GF Value™: €24.49 vs. price of €37.26 (52.1% above fair value)
  • GF Score™: 17/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
17GF Score

Get the complete analysis for FRA:RI2

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.26
Price
€24.49
GF Value